Kristin Hatcher spent three days in Washington, D.C., at the NORD Breakthrough Summit to discuss equitable access to innovation.

Ipsen has achieved progress in the fight against cholestatic diseases, marking two important victories for patients.

With advancements in second-line treatments for PBC in 2024, both current and new treatment options must remain available, so that every patient can choose the treatment that best meets their needs.

Ipsen Pharmaceuticals has just shared exciting news for rare liver disease patients with cholestasis.

We are honored to have had the opportunity to represent the rare liver diseases community at the Alpha-1 Foundation National Conference in Miami, Florida. The weekend was filled with transformative research and thought-provoking conversations.

The GLI Pediatric and Rare Liver Diseases team was thrilled to attend the BARE Symposium on May 10-11, 2024.